Log in to search using one of your social media accounts:


Trethera Corporation Announces FDA Clearance of Investigational New Drug Application for TRE-515

LOS ANGELES, Feb. 5, 2018 -- (Healthcare Sales &Marketing Network) -- Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, today announced that the U.S... Biopharmaceuticals, Oncology, FDA Trethera, TRE-515, deoxycytidine kinase, myelodysplastic syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

More News: Cancer | Cancer & Oncology | Investigational New Drugs | Marketing | Myelodysplastic Syndrome | New Drug Applications | Pharmaceuticals